MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM) — Paul G. Richardson (2021) | RDL Network
MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Cheng Zheng, Franck Dubin, Helgi van de Velde, Kenneth C. Anderson
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Cheng Zheng, Franck Dubin, Helgi van de Velde, Kenneth C. Anderson
Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, Michel Attal, Paul G. Richardson, Anna Marina Liberati, Simon J. Harrison, H. Miles Prince, Enrique M. Ocio, Sylvie Assadourian, Frank Campana, Laure Malinge, Helgi van de Velde, Kwee Yong
Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, Paul G. Richardson, Anna Marina Liberati, Simon J. Harrison, H. Miles Prince, Enrique M. Ocio, Sylvie Assadourian, Frank Campana, Laure Malinge, Dorothée Sémiond, Helgi van de Velde, Kwee Yong
Fredrik Schjesvold, Sara Bringhen, Paul G. Richardson, Aurore Perrot, Xavier Leleu, Philippe Moreau, Meletios A Dimopoulos, Cyrille Hulin, Christina Tekle, Meredith C. Foster, Elizabeth M. Poole, Helgi van de Velde, Thierry Façon
Discussion(0)
No comments yet. Be the first to comment.